SCHEMBL22906372

SCHEMBL22906372

CNCCOCCOCCOCCOCCOCCNC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPK1 P28482 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HIF1A Q16665 1/20 0.44
MTNR1A P48039 4/20 0.43
MTNR1B P49286 4/20 0.43
TSHR P16473 2/20 0.41
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
PAOX Q6QHF9 3/20 0.38
HPGD P15428 1/20 0.37
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22856478 1.00 MEN1 (0.48) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL18908681 1.00 MEN1 (0.48) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL22526372 1.00 MEN1 (0.48) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL10046200 0.98 MAPK1 (0.46) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL22856156 0.94 MEN1 (0.44) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL19309079 0.91 MEN1 (0.56) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL5155263 0.91 MEN1 (0.56) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL18850694 0.90 MAPK1 (0.45) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL21842294 0.89 MEN1 (0.41) MEN1KMT2AMAPK1KDM4EHIF1A
SCHEMBL5157716 0.89 MAPK1 (0.55) MEN1KMT2AMAPK1KDM4EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021119159-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-17 WO disclosed
WO-2021011868-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed
WO-2021011871-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 MEN1 2643/4885KMT2A 1723/4885MAPK1 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.